One of the most consequential discoveries involves the growing problem of drug resistance in blood cancer. Scientists at Sylvester and collaborating institutions have identified a rare genetic mutation that allows certain cancers to escape two generations of therapies aimed at Bruton tyrosine kinase, or BTK. BTK is a signaling protein that helps malignant B cells receive survival and growth signals. In chronic lymphocytic leukemia and related diseases, conventional BTK inhibitors block the protein’s activity, while newer BTK degraders attempt to eliminate the protein altogether. The newly described mutation appears capable of undermining both strategies, revealing how cancer cells can evolve resistance even when therapies attack the same target in different ways.

The work, published in the journal Cancer Discovery, provides a molecular explanation for this cross-resistance and may help guide the design of future treatments. By studying the altered protein and its structural behavior, investigators were able to examine why the mutation prevents both inhibition and degradation. The findings also point toward a potential combination strategy. Researchers reported that pairing a BTK degrader with a drug targeting BCL2, another protein that supports cancer-cell survival, may reduce the likelihood that resistant cells will emerge. This approach reflects a broader shift in oncology: rather than waiting for resistance to appear, physicians and scientists are increasingly attempting to suppress evolutionary escape routes from the beginning of treatment.

A second study suggests that the rules governing stem cell donor selection may be changing for patients with leukemia, lymphoma, myelodysplastic syndromes, and other blood cancers. For decades, transplant teams have generally favored donors whose human leukocyte antigen markers closely matched those of the recipient. These immune-system markers help the body distinguish its own cells from foreign tissue, and mismatches can increase the risk of complications such as graft-versus-host disease, in which donor immune cells attack the patient’s organs. Findings from the ACCESS study, published in Blood Advances, indicate that some patients may achieve encouraging outcomes after receiving transplants from younger, unrelated donors with greater genetic mismatches than traditionally accepted.

The results could expand access to potentially curative transplantation, particularly for patients from ethnically diverse backgrounds who are less likely to find a closely matched donor in existing registries. Donor age and immune biology may influence outcomes alongside the degree of genetic matching, suggesting that transplant decisions could become more individualized. Rather than treating donor compatibility as a single yes-or-no measurement, future models may weigh multiple factors, including age, immune risk, disease status, and the condition of the patient before transplantation. Such a change could shorten searches and make transplantation available to more people who previously had limited donor options.

At the same time, Sylvester is investing in computational tools designed to transform how cancer is studied. An almost $800,000 grant from the National Institutes of Health has funded an NVIDIA N-200 computing platform, an advanced artificial intelligence and high-performance computing system secured by Yan Guo, Ph.D., director of Sylvester’s Biostatistics and Bioinformatics Shared Resource. Cancer research produces enormous quantities of genomic, clinical, imaging, and molecular data. Conventional methods often examine these information streams separately, but machine-learning systems can analyze relationships across them, identifying patterns that may be invisible to human observers or conventional statistical approaches.

The new platform is intended to help researchers search for molecular signatures linked to tumor behavior, treatment response, and patient outcomes. In precision medicine, the goal is to move beyond broad cancer categories and identify the biological features that make an individual tumor vulnerable—or resistant—to a specific therapy. Artificial intelligence does not replace laboratory validation or clinical judgment, but it can accelerate the process of generating and testing hypotheses. By processing large datasets at high speed, the system may help investigators uncover connections between genetic alterations and clinical outcomes, supporting the development of more accurate biomarkers and more targeted treatment strategies.

Cancer research at Sylvester also extends beyond tumor destruction to the long-term effects of treatment. Marlon Wong, P.T., Ph.D., an associate professor of clinical physical therapy, has received a three-year, $225,000 grant from Gabrielle’s Angel Foundation to study chemotherapy-induced peripheral neuropathy. This condition develops when anticancer drugs damage peripheral nerves, particularly those in the hands and feet. Patients may experience burning pain, numbness, tingling, weakness, impaired balance, and difficulty walking or handling objects. Because symptoms can persist long after chemotherapy ends, the condition can affect employment, independence, physical activity, and overall quality of life. Wong’s research will focus on understanding these lasting effects and developing more effective ways to help patients manage them.

The center is also building a pipeline of scientists trained to approach cancer from multiple disciplines. Thirty undergraduate students participated this summer in Sylvester’s 10-week Summer Undergraduate Research Fellowship, working alongside investigators on projects connected to biomedical discovery. Since the program began in 2017, more than 300 students have competed for its 30 positions, making it a highly selective entry point into cancer research. Another initiative, NEXCITE—short for Next-Generation Cancer Internship and Training Excellence—places undergraduates in laboratory environments where they can observe how experiments move from basic biology toward better patient care. Together, the programs expose young researchers to experimental design, data analysis, molecular biology, and the translational process that connects discoveries at the bench with decisions in the clinic.

In lung cancer, Sylvester investigators are advancing both surgery and molecular diagnosis. Nestor Villamizar, M.D., is helping drive the use of robotic and minimally invasive techniques that allow surgeons to operate through small incisions rather than opening the rib cage. Robotic systems provide magnified, three-dimensional visualization and highly controlled instrument movement, potentially reducing surgical trauma, blood loss, pain, and recovery time for appropriately selected patients. In parallel, a large international study led by Sylvester researchers has found that younger adults with non-small cell lung cancer are significantly more likely than older patients to carry genetic alterations that can be matched with targeted therapies. The findings, developed through collaboration with LabCorp and Dana-Farber Cancer Institute, are scheduled for presentation at the 2026 World Conference on Lung Cancer in Seoul. Together, the surgical and genomic advances illustrate a rapidly changing field in which treatment is increasingly shaped by both the physical characteristics of a tumor and the individual biology of the person who has it.

Subject of Research: Cancer research, blood cancer, lung cancer, precision medicine, artificial intelligence, stem cell transplantation, and cancer treatment side effects.

Article Title: Sylvester Cancer Center Advances Blood Cancer Therapies, AI Discovery, Stem Cell Transplants, and Lung Cancer Care

Web References: https://news.med.miami.edu/sylvester-comprehensive-cancer-center-rises-to-no-1-in-florida-and-no-23-in-the-nation/; https://news.med.miami.edu/blood-cancer-btk-resistance-mutation-discovery/; https://news.med.miami.edu/access-trial-expands-stem-cell-donor-options-blood-cancer/; https://news.med.miami.edu/ai-computing-platform-cancer-research-sylvester/; https://news.med.miami.edu/robotic-lung-cancer-surgery-villamizar/; https://news.med.miami.edu/lung-cancer-younger-adults-genetic-alterations-study/

References: Cancer Discovery; Blood Advances; U.S. News & World Report; National Institutes of Health; Gabrielle’s Angel Foundation.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: cancer research, Sylvester Comprehensive Cancer Center, blood cancer, chronic lymphocytic leukemia, BTK inhibitors, BTK degraders, BCL2, stem cell transplantation, artificial intelligence, precision medicine, chemotherapy-induced peripheral neuropathy, lung cancer, robotic surgery, genomic medicine, cancer rankings

Dr. Steidl’s tenure at MECCC has been marked by progressive leadership roles, including program leader, associate director for basic science, and deputy director. His critical contributions extend beyond administration — he has been pivotal in bridging translational research and clinical application, an achievement underscored by his previous position as associate chair for translational research in Montefiore Einstein’s oncology department. In parallel, he has served as interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, further solidifying his expertise in stem cell biology. His academic leadership continues with his role as chair of the Department of Cell Biology at Albert Einstein College of Medicine.

At the core of Dr. Steidl’s research is the intricate biology of blood cancers. Since joining Montefiore Einstein in 2008, he has focused on characterizing pre-leukemic stem cells, elucidating their heterogeneity, and understanding their evolution into leukemic stem cells. This research is transformational, revealing how early stem cell defects precipitate malignant progression. His work highlights the complexity of myelodysplastic syndrome (MDS), a frequent prelude to acute myeloid leukemia (AML). Dr. Steidl’s pioneering insights into the stem cell origin of MDS have shifted the paradigm of blood cancer initiation and progression, offering novel therapeutic targets designed to intercept disease evolution at its earliest stages.

A hallmark of Dr. Steidl’s career is his early demonstration of pre-cancerous stem cells’ existence, a concept now foundational to the field of cancer biology. His research delineated how defective hematopoietic stem cells instigate myelodysplastic syndromes, which further progress into full-blown leukemias. These findings not only deepened scientific understanding but also catalyzed the conceptual framework of ‘precision prevention’ in oncology—the idea that cancers can be intercepted during their earliest, most treatable phases before clinical manifestation. Such an approach advocates for innovative drug development strategies aimed at halting or reversing malignant transformation.

Dr. Steidl’s translational research achievements have had a direct impact on clinical trials, with several experimental drugs targeting leukemic stem cells advancing to human testing. His work lends itself to real-world applications, bridging the gap between bench science and bedside clinical practice. Moreover, Dr. Steidl has pioneered partnerships within the biotech industry, contributing as an inventor to numerous patents and co-founding biotech startups aimed at accelerating therapeutic innovations. This synergy between academic medicine and biotechnology embodies the future of cancer treatment development.

He is also widely recognized for his dedication to mentorship and leadership in the scientific community. Over the years, Dr. Steidl has nurtured a new generation of researchers and clinicians, many of whom have secured faculty and leadership roles at prominent institutions globally. His commitment to fostering talent and collaborative research environments continues to fuel groundbreaking discoveries and broaden the impact of MECCC’s mission.

Dr. Steidl’s outstanding contributions have garnered numerous accolades reflecting his excellence in both science and mentorship. At Albert Einstein College of Medicine, he earned the Saul R. Korey Award in Translational Science and Medicine in 2020 and the Marshall S. Horwitz Award for Research Excellence in 2025. He is a four-time recipient of the Julius Marmur Mentorship Award for Outstanding Mentoring in Graduate Research, highlighting his consistent investment in the growth of emerging scientists.

Beyond institutional honors, Dr. Steidl’s international recognition includes the Scholar Achievement Award from Blood Cancer United (formerly the Leukemia & Lymphoma Society) in 2019 and the Outstanding Investigator Award from the National Cancer Institute in 2021. More recently, the International Society for Experimental Hematology (ISEH) awarded him the McCulloch & Till Award in 2025, the same year he received the prestigious All-Star Award from the V Foundation for Cancer Research.

His election to the Association of American Physicians and the American Society for Clinical Investigation underscores his scientific stature. In addition, serving as both vice president and president of the International Society for Experimental Hematology has allowed Dr. Steidl to steer the direction of hematology research on a global scale. These leadership roles amplify his influence beyond MECCC and demonstrate his commitment to advancing the broader hematological research community.

The Montefiore Einstein Comprehensive Cancer Center, under Dr. Steidl’s leadership, remains at the forefront of cancer research, clinical care, and community engagement. Founded in 1971 and continuously designated by the NCI since 1972, MECCC integrates the scientific excellence of Albert Einstein College of Medicine with the comprehensive, team-oriented clinical care available through Montefiore Health System. Its location in the diverse Bronx borough energizes a mission centered on equity—striving to reduce cancer burdens in underserved and historically underrepresented populations.

MECCC’s dynamic infrastructure fosters innovation across multiple domains, including basic and translational research, clinical trials, education, training, and community outreach. As MECCC advances scientific discovery, it remains dedicated to translating these breakthroughs into meaningful patient outcomes. This commitment embodies the principle that precision medicine, when combined with a holistic approach to healthcare, can transform cancer treatment paradigms locally and globally.

With Dr. Steidl at the helm, MECCC is poised to amplify its impact in cancer science and medicine. His expertise in stem cell biology and translational research aligns with the center’s vision to pioneer strategies that intercept cancer progression early and tailor therapies to individual patient profiles. This strategic direction promises to drive transformative advances, potentially changing the prognosis for many with blood cancers and beyond.

As MECCC continues to attract leading scientists, clinicians, and innovators, Dr. Steidl’s leadership exemplifies the convergence of rigorous research and compassionate clinical care. His deep scientific insight and commitment to mentoring solidify a foundation for sustained excellence. The future of MECCC, under his stewardship, holds promise for breakthroughs that will reshape oncology, elevating patient care and expanding our understanding of cancer biology.

Through his distinguished career and visionary guidance, Dr. Ulrich Steidl is guiding the Montefiore Einstein Comprehensive Cancer Center toward a future where cutting-edge research meets the community’s most pressing cancer challenges. This synergy will undoubtedly forge new pathways toward cancer prevention, interception, and cure, benefiting patients not only in the Bronx but around the world.

Subject of Research: Blood cancer and stem cell biology, focusing on pre-leukemic and leukemic stem cells, myelodysplastic syndromes, and precision prevention strategies.

News Publication Date: April 7, 2026

Web References:

• https://www.einsteinmed.edu/faculty/11118/ulrich-steidl/
• https://montefioreeinstein.org/cancer
• https://montefioreeinstein.org/
• https://einsteinmed.edu/centers/stem-cell
• https://www.nature.com/articles/s41591-018-0267-4

Image Credits: Albert Einstein College of Medicine

Keywords: Cancer, Blood cancer, Stem cells, Leukemia, Myelodysplastic syndrome, Pre-leukemic stem cells, Translational research, Precision prevention, Montefiore Einstein Comprehensive Cancer Center, Ulrich Steidl, Stem cell biology

Central to this symposium is the exploration of protein kinase specificity, a subject extensively addressed by Lewis Cantley, PhD, from the Dana-Farber Cancer Institute. Protein kinases, enzymes critical in cell signaling and regulation, have emerged as pivotal modulators in oncogenesis. Cantley’s discourse elucidates the intricate biochemical networks underpinning kinase activity, emphasizing the therapeutic potential locked within their cellular regulatory mechanisms. This nuanced understanding paves the way for the development of more precise kinase inhibitors, curbing cancer cell proliferation and resistance.

Genomic disparities and their implications on cancer outcomes form a vital theme of the meeting, articulated by Melissa B. Davis, PhD, from Morehouse School of Medicine. Her presentation delves into the systemic inequities embedded within genomic datasets and the consequent population-level cancer disparities. Highlighting the necessity for inclusive genomic research, Davis underscores the role of tailored therapeutic interventions that address the unique molecular profiles of historically underrepresented groups, aiming to reduce the cancer burden equitably across diverse populations.

Another groundbreaking topic is the elucidation of RAS oncogenic signaling pathways and their immune evasion strategies, expertly presented by Julian Downward, PhD, of the Francis Crick Institute. RAS proteins, notorious for their role in driving oncogenesis, have historically been deemed “undruggable” due to their structural complexity. Downward’s insights into the modulation of immune checkpoints and intracellular signaling networks offer promising avenues for therapeutic innovation targeting these elusive oncoproteins, potentially revolutionizing treatment paradigms for RAS-driven malignancies.

The symposium also honors four decades of research on tyrosine phosphorylation, conveyed by Tony Hunter, PhD, from the Salk Institute. Tyrosine phosphorylation, a critical post-translational modification, orchestrates myriad cellular processes including growth and differentiation. Hunter’s retrospective and forward-looking analysis highlights how decades of fundamental biochemical research have culminated in the development of tyrosine kinase inhibitors that have transformed the therapeutic landscape for multiple cancer types, illustrating the profound impact of basic science on clinical advances.

William G. Kaelin Jr., MD, also from Dana-Farber Cancer Institute, addresses the enigmatic VHL (von Hippel-Lindau) tumor suppressor protein. His presentation navigates the complexities of targeting the “undruggable,” focusing on how understanding the VHL pathway’s regulatory role in hypoxia-inducible factors offers unprecedented therapeutic strategies. The molecular intricacies unravelled here hold immense promise in devising treatments that disrupt tumor growth in cancers characterized by VHL inactivation.

Edison T. Liu, MD, of The Jackson Laboratory, brings attention to triple-negative breast cancer (TNBC), a particularly aggressive subtype lacking targeted hormonal therapies. His genomic biology analysis probes the mutational landscape and heterogeneity of TNBC, revealing potential biomarkers and targets for innovative therapies. By integrating genomic sequencing data with clinical phenotypes, Liu’s work exemplifies the precision oncology approach that strives to tailor interventions to the unique genetic makeup of each tumor.

Elaine Mardis, PhD, from The Ohio State University, highlights the genomic diversity observed in acute myeloid leukemia (AML) among Black patients. This focus on genetic variability elucidates treatment outcome disparities and underscores the necessity of incorporating diverse populations in genomic studies. Mardis’s research advocates for personalized medicine strategies that account for racial and ethnic differences in cancer genomics, seeking to optimize therapeutic efficacy and equity.

Continuing at The Ohio State University, W. Kimryn Rathmell, MD, PhD, intriguingly contextualizes the historic and prospective trajectory of UNC Lineberger as a model for comprehensive cancer care. Rathmell’s insights weave together translational research, clinical innovation, and public health initiatives, underscoring the institution’s multifaceted approach to combating cancer. This holistic model exemplifies how integrated efforts enhance patient care and accelerate the translation of discoveries from bench to bedside.

From a public health perspective, Kurt M. Ribisl, PhD, of the UNC Gillings School of Global Public Health, advocates for interdisciplinary strategies in cancer prevention. His discourse emphasizes leveraging epidemiology, behavioral science, and policy to formulate concerted interventions that address cancer risk factors at the population level. Ribisl’s work highlights the critical interface between science and community health, illustrating the importance of preventative frameworks in reducing cancer incidence.

Arlene Sharpe, MD, PhD, of Harvard Medical School, explores the revolutionary use of CRISPR technology in discovering new immunotherapy targets. Her expert analysis demonstrates how genome editing accelerates the identification of molecular pathways that can be manipulated to enhance immune recognition and destruction of cancer cells. Sharpe’s contributions underscore the transformative potential of combining genetic engineering with immuno-oncology to develop next-generation therapies.

Kevan Shokat, PhD, from UC San Francisco, confronts the formidable challenge of drugging K-Ras, a dominant oncogene implicated in numerous cancers. Shokat’s research highlights innovative chemical biology techniques and allosteric modulation approaches that have begun to dismantle previous barriers in targeting K-Ras. His work represents a significant stride towards effective therapeutics against notoriously resistant oncogenic drivers.

Additionally, Melissa Troester, PhD, and Stephanie B. Wheeler, PhD, MPH, both from UNC Gillings School of Global Public Health, champion collaborative frameworks and multimodal data integration to optimize breast cancer care. Troester focuses on harnessing diverse data types—including genomic, histopathologic, and clinical information—to refine prognostic accuracy and treatment personalization. Meanwhile, Wheeler underscores community-engaged approaches and policy initiatives aimed at enhancing cancer care equity within North Carolina.

Kwok-Kin Wong, MD, PhD, of NYU Langone Health, addresses targeted therapeutic strategies for lung squamous cell carcinoma. Highlighting molecular vulnerabilities, Wong’s presentation sheds light on precision medicine approaches that improve outcomes for patients afflicted with this challenging lung cancer subtype.

Finally, Yue Xiong, PhD, from Cullgen Inc., discusses targeted protein degradation as an emerging therapeutic platform. This novel modality leverages the cell’s intrinsic degradation machinery to selectively eliminate oncogenic proteins, presenting a paradigm shift that holds promise across various cancer types.

Collectively, the 48th Annual UNC Lineberger Scientific Symposium integrates an impressive array of scientific advancements and multidisciplinary insights. By traversing molecular biology, clinical research, and population health, the symposium reaffirms its foundational mission: harnessing the full spectrum of cancer research to forge pathways for improved patient outcomes worldwide. Furthermore, the event’s accessibility through livestream and free registration underscores its commitment to disseminating knowledge broadly, fostering global collaboration in the fight against cancer.

Subject of Research: Cancer research continuum including molecular discovery, clinical applications, population health, and therapeutic innovations.

Article Title: Breakthroughs and Perspectives at the 48th Annual UNC Lineberger Scientific Symposium: Advancing the Cancer Research Continuum

Web References:
https://unclineberger.org/symposium/
https://apps2.research.unc.edu/events/index.cfm?event=events.go&key=C96B

Image Credits: UNC Lineberger Comprehensive Cancer Center

Keywords: Cancer, Breast cancer, Leukemia, Pancreatic cancer, Lung cancer